Hans Biomed

Hans Biomed FCF per Share

The Free Cash Flow per Share of Hans Biomed (042520.KQ) as of Nov 1, 2026 is -110.82 KRW. In the previous year, Free Cash Flow per Share was -82.42 KRW — a change of 34.45% (lower).

FCF per Share

-110.82KRW

YoY

34.45%

Last updated:

Free Cash Flow per Share of Hans Biomed is 2025 -110.82 KRW. Free Cash Flow per Share of Hans Biomed was 2024 -82.42 KRW. It decreases by 34.45% lower compared to the previous year.

The Hans Biomed FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2018
301.85 KRW
Jan 1, 2019
-795.95 KRW
Jan 1, 2020
-129.35 KRW
Jan 1, 2021
-1,951.22 KRW
Jan 1, 2022
-856.09 KRW
Jan 1, 2023
-500.97 KRW
Jan 1, 2024
-82.42 KRW
Jan 1, 2025
-110.82 KRW
The Hans Biomed FCF per Share history
YEARFCF per ShareYoY
-110.82KRW+34.45%
-82.42KRW-83.55%
-500.97KRW-41.48%
-856.09KRW-56.13%
-1,951.22KRW+1,408.52%
-129.35KRW-83.75%
-795.95KRW-363.69%
301.85KRW-138.15%
-791.16KRW-25.71%
-1,064.91KRW+186.11%
-372.20KRW-74.77%
-1,475.47KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Hans Biomed Stock analysis

What does Hans Biomed do? Hans Biomed Corp manufactures and sells graft material and silicon products under brand names SureDerm, BellaGen, and GPS for skin-implant materials used in burn treatment and skin graft. The company offers bone-implant materials including allogeneic bones, xenogenous bones, and synthetic bones under SureFuse, ExFuse, and SureOss for dentistry and orthopedic applications. Silicone products such as BellaGel and Scar Clinic are utilized for scar treatment and breast implants. The firm also provides hair transplanters as part of its product portfolio. Skin-implant materials under SureDerm, BellaGen, and GPS are purchased by medical facilities for burn treatment and skin graft procedures. Bone-implant materials under SureFuse, ExFuse, and SureOss are bought by dental and orthopedic clinics for various surgical needs. Silicone products BellaGel and Scar Clinic are acquired by healthcare providers for scar management and breast implant surgeries. Hair transplanters are sold to medical institutions requiring such equipment. The company's primary revenue streams come from the sale of skin-implant materials, bone-implant materials, and silicone products across medical, dental, and orthopedic sectors. Medical facilities, dental clinics, and orthopedic practices represent key customer segments. Brand names SureDerm, BellaGen, GPS, SureFuse, ExFuse, SureOss, BellaGel, and Scar Clinic drive product differentiation and market positioning in the healthcare industry. Hans Biomed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hans Biomed stock

Free Cash Flow per Share of Hans Biomed is -110.82 KRW in 2025.

Free Cash Flow per Share of Hans Biomed changed from -82.42 KRW to -110.82 KRW, representing a 34.45% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share Hans Biomed since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Hans Biomed

All Key Metrics — Hans Biomed